Surgery Partners

▲ Bull Case

• ◆Bain Capital resolves favorably within 18 months—strategic sale to SCA Health/Optum, HCA, or new take-private at $20+/share; equity re-rates 50%+ on resolution alone, removing the governance discount embedded in the current trading multiple
• ◆Deleveraging accelerates—EBITDA growth (~7%) + divestiture proceeds + favorable Term Loan B refinancing in 2027–2028 push leverage below 5.5x by FY2027; multiple re-rates from 10x toward 11.5–12x as credit profile improves, adding $5–8/share
• ◆TJR/spine ASC migration over-delivers—same-facility growth accelerates to 5.5–6.5%, revenue per case rises 5%+ as acuity mix improves, and EBITDA margins recover to 17–18% (vs. 16% today); FY2030 EBITDA reaches $800M+ vs. $725M base case

▼ Bear Case

• ◆Medicare Advantage rate compression accelerates—MA plans (~10% of mix and growing) reset commercial contracts toward traditional Medicare rates at renewal cycles; combined with chronic labor inflation, EBITDA margins compress to 14–15% by FY2027; FCF stays stuck at ~$200M, leverage doesn't materially decline, multiple compresses
• ◆Bain Capital exits at a discount—fund lifecycle forces Bain to monetize via secondary offering at $9–11/share or via a sub-economic take-private at $14–16/share, transferring control with no premium to current public holders; minority shareholders lose the optionality on a clean exit
• ◆Refinancing dislocation in 2027–2028—Term Loan B refinances at 150–250bps wider on either credit spread widening or SGRY-specific credit downgrade; interest expense jumps $40–70M/year, FCF compression triggers covenant scrutiny, equity issuance becomes likely

“The bull side argues SGRY is a levered deleveraging story worth $17–22 on standard sell-side methodology (10.5–11.5x FY2027E EBITDA), with the Bain situation providing free option value. Eleven analysts rate Buy/Strong Buy; average target $17.95 (+33% from current). The bear side argues: (1) NCI economic claim is being mispriced—standard sell-side DCFs don't deduct the ~50% of consolidated EBITDA economically owned by physician JV partners; (2) the leverage discount is structural, not temporary; (3) the Bain rejection at $25.75 may have been the peak, not the floor. The debate hinges on whether NCI should be deducted from valuation (which compresses fair value $8–12/share materially) and whether the Bain overhang resolves up, down, or persists indefinitely.”

• ◆Q2 2026 Earnings (early August 2026)—clean beat on same-facility growth ≥5.0% + EBITDA ≥$140M validates full-year guidance; miss triggers covenant scrutiny
• ◆CMS 2027 ASC Proposed Payment Rule (July–August 2026)—directional impact on ~30% of revenue base; constructive rule supports multi-year trajectory
• ◆Bain Capital 13D/A Filings (ongoing watch)—any change in ownership above ±1% threshold signals event; watch for moves below 25% (loss of blocking rights) or above 39%
• ◆Portfolio Optimization Proceeds Disclosure—$100–200M+ in divestiture proceeds applied to debt visibly accelerates deleveraging narrative
• ◆Q3 2026 Earnings (mid-November)—historically strongest margin quarter; sets up FY2026 EBITDA print and FY2027 setup
• ◆Term Loan B Refinancing News (any time FY2026–FY2027)—early refinancing at favorable spread meaningfully de-risks the 2028 maturity wall

• ◆Bain Capital adverse action—block sale at discount, predatory take-private at sub-intrinsic price, or extended dormancy indefinitely embedding governance discount (HIGH impact, ONGOING likelihood)
• ◆EBITDA miss + covenant scrutiny—any 2-quarter EBITDA stumble at 6.6x leverage triggers credit concern; equity volatility amplified by leverage (HIGH impact, MODERATE likelihood)
• ◆Medicare Advantage commercial rate reset—MA plans renegotiating ASC contracts toward traditional Medicare; structural margin compression (MEDIUM impact, HIGH likelihood; chronic)
• ◆Labor cost re-acceleration—surgical nurse / OR tech shortage; SGRY's 60%+ labor cost ratio amplifies any wage inflation (HIGH impact, MODERATE likelihood)
• ◆Refinancing dislocation—2028 TLB maturity could refinance at 150–250bps wider if credit conditions tighten (HIGH impact, LOW-MODERATE likelihood)
• ◆Strategic competition—SCA Health (Optum/UnitedHealth), HCA, and health-system ASC builds compete for surgeons; switching costs real but not absolute (MEDIUM impact, MODERATE-HIGH likelihood)
• ◆Stark Law / Anti-Kickback enforcement—physician JV model operates under specific exemptions; aggressive enforcement could threaten the model (HIGH impact, LOW likelihood)